Evidence & Performance Blog

Assessing the performance of CROs

Pharmaceutical and biotech companies want to speed up the research and development process whilst adhering to stricter guidelines. That’s why CRO’s are primarily selected on their scientific expertise and the cost/value ratio.

If R&D companies have always had a ‘feeling’ about their CRO, they are now more and more looking for facts in assessing their performance. This can only be done by “Choosing the right metrics” and “Deploying the right tools to evaluate these metrics”. Read more

As the sponsors are more and more focused on the clinical trial performance, they now also seem focused on their service providers. Let’s see why they are interested in their provider’s performance, how they can get to results and at the bottom line what impact it will have on their future trials. Read more

All new medical products (drugs and medical devices) must follow harsh process of clinical development.

Starting from the earliest stage to very last step in the process of the clinical trial, there is place for potential delays and unexpected costs. Read more